News

Ability Pharma sponsors the 37th National Meeting of the Spanish Society of Pharmacology

March 3, 2017

Barcelona (Catalonia, Spain), March 7, 2017. Ability Pharmaceuticals, a drug development biopharmaceutical company specialized in oncology, announced the sponsorship of the of 37th National Meeting of the Spanish Society of Pharmacology (SEF). The Meeting will be held in Barcelona from Sunday 18th to Wednesday 21th June 2017, with the British Pharmacological Society (BPS) as the main guest (http://www.sef2017.com).
 
This meeting will display the world class research carried out not only by SEF and BPS members but also by researchers worldwide whose investigation revolves around the pharmacology field. The programme combines plenary lectures, symposia, oral presentations and posters, to stimulate the scientific discussion as well as to set new collaborations and research opportunities especially for young researchers.
 
Dr. José Alfón, the VP of research and developmend of Ability Pharma, will be opening the Session 14 (Pharmacology of Anti-Cancer Drugs) on Wednesday 21th June, presenting our main project ABTL0812, an autophagy-anticancer drug in Phase II clinical trials.

LATEST NEWS

12.09.2019

News

AbilityPharma rises € 3.5 million in a financing round to complete the current oncologic phase 2 clinical trial and license ABTL0812 to an international pharmaceutical company + info
31.05.2019

News

Ability Pharmaceuticals Announces the Presentation of the First Results of ABTL0812 as First Line in Patients with Endometrial or Lung Cancer at 2019 ASCO Annual Meeting + info
04.02.2019

News

Ability Pharmaceuticals Announces the Approval in China of a Clinical Study in Pancreatic Cancer with ABTL0812 + info
30.01.2019

News

Ability Pharmaceuticals is attending the BIOMED EVENT® by INVEST SECURITIES and the Cholangiocarcinoma Foundation Annual Conference + info
05.12.2018

News

AbilityPharma ha superado el millón de euros en la ronda de crowdfunding que abrió el pasado mes de septiembre + info
07.11.2018

News

Ability Pharmaceuticals Announces FDA-Orphan Drug Designation for ABTL0812 in Biliary Tract Cancer + info
19.09.2018

News

Ability Pharmaceuticals anuncia la inclusión del primer paciente en el estudio clínico de la fase 2 de ABTL0812 en Francia + info
24.08.2018

News

At AbilityPharma we are very pleased to announce the start of a crowdfunding campaign through de Capital Cell + info
19.02.2018

News

AbilityPharma Announces FDA Approval of Phase 1/2 Trial of ABTL0812 for Patients with Advanced Metastatic Pancreatic Cancer + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
NEORG